The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase

Giorgia Mori, Beatrice Silvia Orena, Clara Franch, Lesley A. Mitchenall, Adwait Anand Godbole, Liliana Rodrigues, Clara Aguilar-Pérez, Júlia Zemanová, Stanislav Huszár, Martin Forbak, Thomas R. Lane, Mohamad Sabbah, Nathalie Deboosere, Rosangela Frita, Alexandre Vandeputte, Eik Hoffmann, Riccardo Russo, Nancy Connell, Courtney Veilleux, Rajiv KumarPradeep Kumar, Joel S. Freundlich, Priscille Brodin, Jose Antonio Aínsa, Valakunja Nagaraja, Anthony Maxwell, Katarína Mikušová, Maria Rosalia Pasca, Sean Ekins

Research output: Contribution to journalArticle

Abstract

The search for compounds with biological activity for many diseases is turning increasingly to drug repurposing. In this study, we have focused on the European Union-approved antimalarial pyronaridine which was found to have in vitro activity against Mycobacterium tuberculosis (MIC 5 μg/mL). In macromolecular synthesis assays, pyronaridine resulted in a severe decrease in incorporation of 14 C-uracil and 14 C-leucine similar to the effect of rifampicin, a known inhibitor of M. tuberculosis RNA polymerase. Surprisingly, the co-administration of pyronaridine (2.5 μg/ml) and rifampicin resulted in in vitro synergy with an MIC 0.0019–0.0009 μg/mL. This was mirrored in a THP-1 macrophage infection model, with a 16-fold MIC reduction for rifampicin when the two compounds were co-administered versus rifampicin alone. Docking pyronaridine in M. tuberculosis RNA polymerase suggested the potential for it to bind outside of the RNA polymerase rifampicin binding pocket. Pyronaridine was also found to have activity against a M. tuberculosis clinical isolate resistant to rifampicin, and when combined with rifampicin (10% MIC) was able to inhibit M. tuberculosis RNA polymerase in vitro. All these findings, and in particular the synergistic behavior with the antitubercular rifampicin, inhibition of RNA polymerase in combination in vitro and its current use as a treatment for malaria, may suggest that pyronaridine could also be used as an adjunct for treatment against M. tuberculosis infection. Future studies will test potential for in vivo synergy, clinical utility and attempt to develop pyronaridine analogs with improved potency against M. tuberculosis RNA polymerase when combined with rifampicin.

Original languageEnglish (US)
Pages (from-to)98-109
Number of pages12
JournalTuberculosis
Volume112
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Antimalarials
DNA-Directed RNA Polymerases
Rifampin
Mycobacterium tuberculosis
Drug Repositioning
pyronaridine
Mycobacterium Infections
Uracil
European Union
Leucine
Malaria
Macrophages
In Vitro Techniques
Infection

Keywords

  • Antimalarial
  • Gyrase
  • Mycobacterium tuberculosis
  • Pyronaridine
  • Repurposing
  • RNA polymerase
  • Topoisomerase
  • Tuberculosis

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Mori, G., Orena, B. S., Franch, C., Mitchenall, L. A., Godbole, A. A., Rodrigues, L., ... Ekins, S. (2018). The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. Tuberculosis, 112, 98-109. https://doi.org/10.1016/j.tube.2018.08.004

The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. / Mori, Giorgia; Orena, Beatrice Silvia; Franch, Clara; Mitchenall, Lesley A.; Godbole, Adwait Anand; Rodrigues, Liliana; Aguilar-Pérez, Clara; Zemanová, Júlia; Huszár, Stanislav; Forbak, Martin; Lane, Thomas R.; Sabbah, Mohamad; Deboosere, Nathalie; Frita, Rosangela; Vandeputte, Alexandre; Hoffmann, Eik; Russo, Riccardo; Connell, Nancy; Veilleux, Courtney; Kumar, Rajiv; Kumar, Pradeep; Freundlich, Joel S.; Brodin, Priscille; Aínsa, Jose Antonio; Nagaraja, Valakunja; Maxwell, Anthony; Mikušová, Katarína; Pasca, Maria Rosalia; Ekins, Sean.

In: Tuberculosis, Vol. 112, 01.09.2018, p. 98-109.

Research output: Contribution to journalArticle

Mori, G, Orena, BS, Franch, C, Mitchenall, LA, Godbole, AA, Rodrigues, L, Aguilar-Pérez, C, Zemanová, J, Huszár, S, Forbak, M, Lane, TR, Sabbah, M, Deboosere, N, Frita, R, Vandeputte, A, Hoffmann, E, Russo, R, Connell, N, Veilleux, C, Kumar, R, Kumar, P, Freundlich, JS, Brodin, P, Aínsa, JA, Nagaraja, V, Maxwell, A, Mikušová, K, Pasca, MR & Ekins, S 2018, 'The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase', Tuberculosis, vol. 112, pp. 98-109. https://doi.org/10.1016/j.tube.2018.08.004
Mori, Giorgia ; Orena, Beatrice Silvia ; Franch, Clara ; Mitchenall, Lesley A. ; Godbole, Adwait Anand ; Rodrigues, Liliana ; Aguilar-Pérez, Clara ; Zemanová, Júlia ; Huszár, Stanislav ; Forbak, Martin ; Lane, Thomas R. ; Sabbah, Mohamad ; Deboosere, Nathalie ; Frita, Rosangela ; Vandeputte, Alexandre ; Hoffmann, Eik ; Russo, Riccardo ; Connell, Nancy ; Veilleux, Courtney ; Kumar, Rajiv ; Kumar, Pradeep ; Freundlich, Joel S. ; Brodin, Priscille ; Aínsa, Jose Antonio ; Nagaraja, Valakunja ; Maxwell, Anthony ; Mikušová, Katarína ; Pasca, Maria Rosalia ; Ekins, Sean. / The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. In: Tuberculosis. 2018 ; Vol. 112. pp. 98-109.
@article{0d3c2813e63c471ca07da4e8129b0a71,
title = "The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase",
abstract = "The search for compounds with biological activity for many diseases is turning increasingly to drug repurposing. In this study, we have focused on the European Union-approved antimalarial pyronaridine which was found to have in vitro activity against Mycobacterium tuberculosis (MIC 5 μg/mL). In macromolecular synthesis assays, pyronaridine resulted in a severe decrease in incorporation of 14 C-uracil and 14 C-leucine similar to the effect of rifampicin, a known inhibitor of M. tuberculosis RNA polymerase. Surprisingly, the co-administration of pyronaridine (2.5 μg/ml) and rifampicin resulted in in vitro synergy with an MIC 0.0019–0.0009 μg/mL. This was mirrored in a THP-1 macrophage infection model, with a 16-fold MIC reduction for rifampicin when the two compounds were co-administered versus rifampicin alone. Docking pyronaridine in M. tuberculosis RNA polymerase suggested the potential for it to bind outside of the RNA polymerase rifampicin binding pocket. Pyronaridine was also found to have activity against a M. tuberculosis clinical isolate resistant to rifampicin, and when combined with rifampicin (10{\%} MIC) was able to inhibit M. tuberculosis RNA polymerase in vitro. All these findings, and in particular the synergistic behavior with the antitubercular rifampicin, inhibition of RNA polymerase in combination in vitro and its current use as a treatment for malaria, may suggest that pyronaridine could also be used as an adjunct for treatment against M. tuberculosis infection. Future studies will test potential for in vivo synergy, clinical utility and attempt to develop pyronaridine analogs with improved potency against M. tuberculosis RNA polymerase when combined with rifampicin.",
keywords = "Antimalarial, Gyrase, Mycobacterium tuberculosis, Pyronaridine, Repurposing, RNA polymerase, Topoisomerase, Tuberculosis",
author = "Giorgia Mori and Orena, {Beatrice Silvia} and Clara Franch and Mitchenall, {Lesley A.} and Godbole, {Adwait Anand} and Liliana Rodrigues and Clara Aguilar-P{\'e}rez and J{\'u}lia Zemanov{\'a} and Stanislav Husz{\'a}r and Martin Forbak and Lane, {Thomas R.} and Mohamad Sabbah and Nathalie Deboosere and Rosangela Frita and Alexandre Vandeputte and Eik Hoffmann and Riccardo Russo and Nancy Connell and Courtney Veilleux and Rajiv Kumar and Pradeep Kumar and Freundlich, {Joel S.} and Priscille Brodin and A{\'i}nsa, {Jose Antonio} and Valakunja Nagaraja and Anthony Maxwell and Katar{\'i}na Mikušov{\'a} and Pasca, {Maria Rosalia} and Sean Ekins",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.tube.2018.08.004",
language = "English (US)",
volume = "112",
pages = "98--109",
journal = "Tuberculosis",
issn = "1472-9792",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase

AU - Mori, Giorgia

AU - Orena, Beatrice Silvia

AU - Franch, Clara

AU - Mitchenall, Lesley A.

AU - Godbole, Adwait Anand

AU - Rodrigues, Liliana

AU - Aguilar-Pérez, Clara

AU - Zemanová, Júlia

AU - Huszár, Stanislav

AU - Forbak, Martin

AU - Lane, Thomas R.

AU - Sabbah, Mohamad

AU - Deboosere, Nathalie

AU - Frita, Rosangela

AU - Vandeputte, Alexandre

AU - Hoffmann, Eik

AU - Russo, Riccardo

AU - Connell, Nancy

AU - Veilleux, Courtney

AU - Kumar, Rajiv

AU - Kumar, Pradeep

AU - Freundlich, Joel S.

AU - Brodin, Priscille

AU - Aínsa, Jose Antonio

AU - Nagaraja, Valakunja

AU - Maxwell, Anthony

AU - Mikušová, Katarína

AU - Pasca, Maria Rosalia

AU - Ekins, Sean

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The search for compounds with biological activity for many diseases is turning increasingly to drug repurposing. In this study, we have focused on the European Union-approved antimalarial pyronaridine which was found to have in vitro activity against Mycobacterium tuberculosis (MIC 5 μg/mL). In macromolecular synthesis assays, pyronaridine resulted in a severe decrease in incorporation of 14 C-uracil and 14 C-leucine similar to the effect of rifampicin, a known inhibitor of M. tuberculosis RNA polymerase. Surprisingly, the co-administration of pyronaridine (2.5 μg/ml) and rifampicin resulted in in vitro synergy with an MIC 0.0019–0.0009 μg/mL. This was mirrored in a THP-1 macrophage infection model, with a 16-fold MIC reduction for rifampicin when the two compounds were co-administered versus rifampicin alone. Docking pyronaridine in M. tuberculosis RNA polymerase suggested the potential for it to bind outside of the RNA polymerase rifampicin binding pocket. Pyronaridine was also found to have activity against a M. tuberculosis clinical isolate resistant to rifampicin, and when combined with rifampicin (10% MIC) was able to inhibit M. tuberculosis RNA polymerase in vitro. All these findings, and in particular the synergistic behavior with the antitubercular rifampicin, inhibition of RNA polymerase in combination in vitro and its current use as a treatment for malaria, may suggest that pyronaridine could also be used as an adjunct for treatment against M. tuberculosis infection. Future studies will test potential for in vivo synergy, clinical utility and attempt to develop pyronaridine analogs with improved potency against M. tuberculosis RNA polymerase when combined with rifampicin.

AB - The search for compounds with biological activity for many diseases is turning increasingly to drug repurposing. In this study, we have focused on the European Union-approved antimalarial pyronaridine which was found to have in vitro activity against Mycobacterium tuberculosis (MIC 5 μg/mL). In macromolecular synthesis assays, pyronaridine resulted in a severe decrease in incorporation of 14 C-uracil and 14 C-leucine similar to the effect of rifampicin, a known inhibitor of M. tuberculosis RNA polymerase. Surprisingly, the co-administration of pyronaridine (2.5 μg/ml) and rifampicin resulted in in vitro synergy with an MIC 0.0019–0.0009 μg/mL. This was mirrored in a THP-1 macrophage infection model, with a 16-fold MIC reduction for rifampicin when the two compounds were co-administered versus rifampicin alone. Docking pyronaridine in M. tuberculosis RNA polymerase suggested the potential for it to bind outside of the RNA polymerase rifampicin binding pocket. Pyronaridine was also found to have activity against a M. tuberculosis clinical isolate resistant to rifampicin, and when combined with rifampicin (10% MIC) was able to inhibit M. tuberculosis RNA polymerase in vitro. All these findings, and in particular the synergistic behavior with the antitubercular rifampicin, inhibition of RNA polymerase in combination in vitro and its current use as a treatment for malaria, may suggest that pyronaridine could also be used as an adjunct for treatment against M. tuberculosis infection. Future studies will test potential for in vivo synergy, clinical utility and attempt to develop pyronaridine analogs with improved potency against M. tuberculosis RNA polymerase when combined with rifampicin.

KW - Antimalarial

KW - Gyrase

KW - Mycobacterium tuberculosis

KW - Pyronaridine

KW - Repurposing

KW - RNA polymerase

KW - Topoisomerase

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85051375150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051375150&partnerID=8YFLogxK

U2 - 10.1016/j.tube.2018.08.004

DO - 10.1016/j.tube.2018.08.004

M3 - Article

C2 - 30205975

AN - SCOPUS:85051375150

VL - 112

SP - 98

EP - 109

JO - Tuberculosis

JF - Tuberculosis

SN - 1472-9792

ER -